|
Apr 22
|
Trump’s FDA Sends a Bullish Signal to Biotech
|
|
Apr 21
|
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
|
|
Apr 4
|
Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN
|
|
Apr 3
|
IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility
|
|
Apr 3
|
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy
|
|
Apr 1
|
Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?
|
|
Apr 1
|
Biotech stocks slide as Marks resignation seen being negative for sector
|
|
Mar 31
|
Intellia Focuses on Pipeline Development Amid Stiff Competition
|
|
Mar 1
|
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
|
|
Feb 28
|
NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y
|
|
Feb 28
|
Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations
|
|
Feb 28
|
Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...
|
|
Feb 28
|
Q4 2024 Intellia Therapeutics Inc Earnings Call
|
|
Feb 27
|
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 27
|
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress
|
|
Feb 25
|
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
|
|
Feb 14
|
Intellia Therapeutics (NTLA): Among The Small–Cap Stocks Insiders Are Selling Recently
|
|
Feb 14
|
Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?
|
|
Dec 30
|
Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In?
|
|
Oct 17
|
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|